NEW YORK – Bayer on Wednesday announced that the first patient has been enrolled in the Target Rare Cancer Knowledge (TRACK) study.
NEW YORK – Bayer on Wednesday announced that the first patient has been enrolled in the Target Rare Cancer Knowledge (TRACK) study.
...and receive Weekly News bulletins.
Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.
Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.